Article: CFTR modulators: transformative therapies for cystic fibrosis

No funding contributed to the writing of this commentary. Both authors are employed by the Cystic Fibrosis Foundation. The Cystic Fibrosis Foundation has entered into therapeutic development award agreements and licensing agreements to assist with the development of CFTR modulators that may result in intellectual property rights, royalties, and other forms of consideration provided to CFF. Some of these agreements are subject to confidentiality restrictions and, thus, CFF cannot comment on them.

Citing Articles

Clinical Outcomes in Patients with Cystic Fibrosis Receiving CFTR Modulators: A Comparison of Childhood Versus Adolescent Initiation.

Toraih E, Malik H, Islam R, Pirzadah H, Abdelmaksoud A, Elshazli R Children (Basel). 2025; 12(2).

PMID: 40003259 PMC: 11854606. DOI: 10.3390/children12020157.

Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis.

Koenig C, Monogue M, Shields R, Sakon C, Fratoni A, Roenfanz H Antimicrob Agents Chemother. 2024; 69(1):e0153924.

PMID: 39655913 PMC: 11784235. DOI: 10.1128/aac.01539-24.

Symptom phenotyping in people with cystic fibrosis during acute pulmonary exacerbations using machine-learning K-means clustering analysis.

Gill E, Dill C, Goss C, Sagel S, Wright M, Horner S J Cyst Fibros. 2024; 23(6):1106-1111.

PMID: 38851922 PMC: 11624099. DOI: 10.1016/j.jcf.2024.05.014.

Improved recognition of lung function decline as signal of cystic fibrosis pulmonary exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory quality improvement initiative.

List R, Solomon G, Bichl S, Horton B, Shen S, Corcoran B BMJ Open Qual. 2023; 12(4).

PMID: 38154821 PMC: 10759080. DOI: 10.1136/bmjoq-2023-002466.

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.

Schechter M, Sabater-Anaya N, Oster G, Weycker D, Wu H, Arteaga-Solis E Pulm Ther. 2023; 9(4):479-498.

PMID: 37874528 PMC: 10721580. DOI: 10.1007/s41030-023-00241-z.

References

1.

Sawicki G, McKone E, Pasta D, Millar S, Wagener J, Johnson C . Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015; 192(7):836-42. DOI: 10.1164/rccm.201503-0578OC. View

2.

Konstan M, McKone E, Moss R, Marigowda G, Tian S, Waltz D . Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2016; 5(2):107-118. DOI: 10.1016/S2213-2600(16)30427-1. View

3.

Rosenfeld M, Wainwright C, Higgins M, Wang L, McKee C, Campbell D . Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018; 6(7):545-553. PMC: 6626762. DOI: 10.1016/S2213-2600(18)30202-9. View

4.

Middleton P, Mall M, Drevinek P, Lands L, McKone E, Polineni D . Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019; 381(19):1809-1819. PMC: 7282384. DOI: 10.1056/NEJMoa1908639. View

CFTR Modulators: Transformative Therapies for Cystic Fibrosis